Elisabetta Bonzano, Medical Director and Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared a post on X about a paper by Chiara Corti et al. published in ESMO Open:
“Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study.
Prosigna is FDA-cleared in postoperative hormone receptor-positive BC specimens.
Previous studies demonstrated that Prosigna may identify chemosensitive tumors.
We analyzed whether the assay influenced physicians’ choices and patients’ confidence in the neoadjuvant treatment plan.
A change in the treatment plan occurred in 35.2% of cases (95% CI 23.1%-50.2%).
83.7% of physicians maintained or improved confidence in the treatment plan, and 62.5% of patients reported less anxiety.
Performing Prosigna on upfront core biopsies may influence the neoadjuvant treatment decision-making in early-stage HR-positive/HER2-negative BC.”
Title: Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study
Authors: C. Corti, X. Chu, P. Exman, D.M. Kline, N.M. Priedigkeit, E.L. Mayer, A.G. Waks, M.E. Hughes, D.L Abravanel, A. Giordano, G. Curigliano, N.U. Lin, T.A. King, R.M. Jeselsohn, D.K. Manning, D.A. Dillon, E.A. Mittendorf, N. Tayob, S.M. Tolaney
You can read the Full Article in ESMO Open.
More posts featuring Elisabetta Bonzano on OncoDaily.
